Biotech Firm Accelerates Drug Discovery 60% with AI Platform
How we helped a leading biotech company transform their research workflows with an enterprise AI/ML platform powered by IBM watsonx.
Reduction in drug discovery timeline
Research data in unified platform
Improvement in ML model iteration
Data Fragmentation Slowing Research
The biotech firm was struggling with siloed data and manual processes that slowed their critical drug discovery research, with GPU resources poorly utilized across disparate systems.
Data Fragmentation
Research data scattered across multiple systems with no unified view for AI/ML workflows
Slow Model Training
GPU resources were scarce and poorly utilized, creating bottlenecks in ML experimentation
Compliance Concerns
FDA and HIPAA requirements demanded strict data lineage and security controls
Enterprise AI Platform for Life Sciences
Li9 designed an enterprise AI/ML platform using IBM watsonx and Red Hat OpenShift optimized for biotech research with full compliance and governance.
IBM watsonx.ai
Enterprise AI platform with pre-trained foundation models optimized for life sciences research
GPU-Enabled OpenShift
Red Hat OpenShift with NVIDIA GPU support for accelerated model training at scale
Compliant Data Fabric
IBM watsonx.data with full lineage tracking and FDA/HIPAA compliance built-in
Breakthrough Research Velocity
The AI platform transformation delivered breakthrough improvements in research velocity and efficiency.
Key Takeaway
By implementing an enterprise AI platform with IBM watsonx and GPU-accelerated OpenShift, Li9 helped this biotech firm reduce drug discovery timelines by 60% while achieving full FDA and HIPAA compliance.
Technologies & Platforms
IBM watsonx.aiIBM watsonx.data
Red Hat OpenShiftReady to Accelerate Your AI Initiative?
Let's discuss how Li9 can help you build an enterprise AI platform for your research.